JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

From JAMA: is associated with higher risk for 12 types and accounts for approximately 10% of annual new cancer cases...
03/09/2026

From JAMA: is associated with higher risk for 12 types and accounts for approximately 10% of annual new cancer cases in the US.

Excess adiposity promotes cancer development through inflammation, altered hormone production, disrupted immune function, genomic instability, and gut microbiome changes.

interventions, including and glucagon-like peptide 1 receptor agonists ( -1 RAs), have been linked to modest reductions in obesity-associated cancer risk, although >10% weight loss may be necessary for measurable benefit.

📄 This Review summarizes the primary biological pathways connecting obesity and cancer development.

https://ja.ma/4aZZVqZ

Older adults with advanced mainly prioritized quality of life, but their treatment preferences were not associated wit...
03/09/2026

Older adults with advanced mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects.

https://ja.ma/4uANw4D

Cancer treatments work by attacking cancer cells that grow fast. But sometimes these treatments also damage healthy cell...
03/08/2026

Cancer treatments work by attacking cancer cells that grow fast. But sometimes these treatments also damage healthy cells in your mouth, that cause mouth problems. Your mouth health can be affected at any time during your cancer treatment.

📄 This JAMA Oncology Patient Page describes different types of common mouth problems during treatment and how to care for them.

https://ja.ma/4cfiPep

This phase 2 nonrandomized clinical trial evaluated oral upadacitinib for severe immune checkpoint inhibitor–related der...
03/07/2026

This phase 2 nonrandomized clinical trial evaluated oral upadacitinib for severe immune checkpoint inhibitor–related dermatitis in patients with solid tumors.

Rash resolution to grade ≤1 was achieved in all participants within 28 days, and pruritus improvement was reported within 1 day of initiation. Upadacitinib was well tolerated, with no serious treatment-related adverse events.

The majority of patients were able to continue immune checkpoint inhibitor therapy as scheduled, indicating the potential of upadacitinib as a safe and effective option for managing severe induced by immunotherapy.

https://ja.ma/4bgGOZC

This secondary analysis of a cluster randomized clinical trial examined outcomes in older adults (age ≥70 years) with ad...
03/06/2026

This secondary analysis of a cluster randomized clinical trial examined outcomes in older adults (age ≥70 years) with advanced cancer who prioritized maintaining quality of life vs prolonging survival.

Of the 706 patients, more than 70% valued quality of life over survival, yet no significant differences were found between groups for survival, hospitalization, or treatment-related adverse effects.

These findings indicate the current oncology care delivery system may lack responsiveness to patient preferences, supporting the need for strategies that integrate preference-concordant care.

https://ja.ma/4tVJu6h

Among patients with advanced solid tumors in the Australian Molecular Screening and Therapeutic program, genomic therapy...
03/05/2026

Among patients with advanced solid tumors in the Australian Molecular Screening and Therapeutic program, genomic therapy matching based on a tiered evidence framework was associated with improved overall survival when the biomarker-drug pair was supported by prospective clinical trial evidence.

Patients receiving genomically matched therapy with clinical trial–level evidence had a median overall survival of 21.2 months vs 12.8 months for unmatched therapy.

No survival benefit was observed for treatments matched using investigational or repurposed evidence (tiers 3B/4).

https://ja.ma/4rLSFou

Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term o...
03/03/2026

Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term organ preservation and favorable local recurrence rates for patients who declined rhinectomy or had unresectable disease. https://ja.ma/4rO60vZ

Broader sharing of clinical trial data and biospecimens enables personalized , but access and collaboration among acade...
03/02/2026

Broader sharing of clinical trial data and biospecimens enables personalized , but access and collaboration among academia, industry, and patients remain suboptimal.

📢 This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration.

https://ja.ma/4cvZhm2

In an international multicenter cohort study, adjuvant imatinib therapy following curative surgery was associated with i...
03/01/2026

In an international multicenter cohort study, adjuvant imatinib therapy following curative surgery was associated with improved recurrence-free survival and overall survival among patients with gastrointestinal stromal tumors ( ) harboring KIT exon 9 mutations.

The benefit was most evident in patients classified as high risk according to modified National Institutes of Health criteria.

No significant differences in outcomes were observed between 400 mg/d vs 800 mg/d dosing in the adjuvant setting. These results provide the strongest evidence to date supporting adjuvant imatinib in this molecular subgroup, despite relative dose insensitivity.

https://ja.ma/46nOdDR

Immune checkpoint inhibitor–induced occurred in 0.52% of patients across 158 National Cancer Institute trials, with hi...
03/01/2026

Immune checkpoint inhibitor–induced occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with . https://ja.ma/3OihlpM

💬 Editorial: Most women in the WISDOM trial preferred tailored, risk-based screening, highlighting its patient accepta...
02/28/2026

💬 Editorial: Most women in the WISDOM trial preferred tailored, risk-based screening, highlighting its patient acceptability and supporting a shift from age-based protocols.

https://ja.ma/4sbCII7

Among over 7000 patients with , higher baseline fatigue before systemic therapy was linked to an increased risk of seve...
02/28/2026

Among over 7000 patients with , higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. https://ja.ma/3OKeENN

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category